Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“ADC + tucatinib combinations are emerging in HER2+ metastatic breast cancer.
In the phase III HER2CLIMB-02 trial, adding tucatinib to the ADC T-DM1 improved PFS:
- 9.5 vs 7.4 months (HR 0.76).
- Brain metastases subgroup HR 0.64.
Benefit was achieved with a manageable safety profile. Results of trastuzumab deruxtecan + tucatinib are eagerly awaited – prior data already suggest clear biologic synergy between tucatinib and ADCs.”
Title: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
Authors: S. A. Hurvitz, S. Loi, J. O’Shaughnessy, A. F. C. Okines, S. M. Tolaney, J. Sohn, C. Saura, X. Zhu, D. Cameron, T. Bachelot, E. Hamilton, G. Curigliano, A. C. Wolff, N. Harbeck, N. Masuda, L. Vahdat, K. Zaman, F. Valdes-Albini, M. Block, T. Pluard, T. J. Tan, C. Gawryletz, A. Chan, P. L. Bedard, R. Yerushalmi, B. Xu, M. Schmitt, D. Xie, V. F. Borges
Read The Full Article
Other articles about ADC on OncoDaily.
